In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Micromet, Inc.

http://www.micromet.de

Latest From Micromet, Inc.

Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE

Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.

Gene Therapy Clinical Trials

ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma

The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.

Business Strategies Clinical Trials

Zealand Nabs Novo Nordisk To Save Zegalogue Launch

US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.

Metabolic Disorders Deals

Saniona Seeks Partners To Secure Survival

CEO Thomas Feldthus's new broom is sweeping clean at Saniona with the closure of its US operations and an aim of exploiting the significant interest being shown across its pipeline programs.

Restructuring Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • CancerVax Corporation
UsernamePublicRestriction

Register